StockData

Orchestra BioMed Holdings, Inc. (OBIO) company profile

OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$6.97−0.15 (-2.11%)

Close on Nov 17, 2026Market cap $418.93MP/E –Yield –

About Orchestra BioMed

Surgical & Medical Instruments & Apparatus, SIC 3841

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic medical technologies through risk-and-reward sharing partnerships with major global medical device companies. The company operates across two principal product development platforms: bioelectronic therapies and interventional devices. Its flagship bioelectronic candidate, Atrioventricular Interval Modulation (AVIM) Therapy, is an algorithmic, firmware-integrated treatment for uncontrolled hypertension in cardiac pacemaker patients, being co-developed under an exclusive global license and collaboration with Medtronic. Its lead interventional candidate, the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), is a drug-device combination delivering an extended-release sirolimus formulation for treating atherosclerotic artery disease, specifically targeting coronary in-stent restenosis and related vascular conditions.

The company's clinical research activities span multiple worldwide regions, including a global pivotal trial conducted across up to 130 sites globally for AVIM Therapy and a United States pivotal trial enrolling patients across up to 75 domestic sites for Virtue SAB. Orchestra BioMed operates primarily through collaboration frameworks with multinational device distributors and partners. The company's headquarters are not stated in the provided text.

Summary of the business section of Orchestra BioMed's latest annual report, written by StockData.

Company profile

Company

Legal name
Orchestra BioMed Holdings, Inc.
Founded
2018
Headquarters
New Hope, PA
Address
150 Union Square Drive 18938
Phone
(646) 343-9298
Employees
86, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
OBIO
Former tickers
HSAQ until Jan 31, 2023
Exchange
Nasdaq
IPO date
Aug 5, 2020
Shares outstanding
60M, Aug 6, 2026
Public float
$63.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-1.33 reverse, Nov 12, 2021
SEC CIK
1814114
CUSIP
68572M106
ISIN
US68572M1062
FIGI
BBG00W5FR2T5
Share class FIGI
BBG00W5FR3L1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David P. HochmanSee Remarks, Director1,514,519
Darren ShermanSee Remarks, Director1,106,402
Andrew Lawrence TaylorChief Financial Officer590,989
Joshua AielloPrincipal Accounting Officer18,441
Eric S. FainDirector127,130
David PacittiDirector74,750
John Prosper MackDirector66,544
Chris ClearyDirector29,153
Pamela Ann ConnealyDirector66,038
Jason AryehDirector118,118

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
David P. Hochman
Chief Executive Officer & Chairman
$595.00K$791.40K$290.58K$572.01K$12.25K$2.26M+18%
Darren R. Sherman
President & Chief Operating Officer
$495.00K$631.35K$84.84K$475.87K$70.77K$1.76M-2%
Andrew L. Taylor
Chief Financial Officer
$409.58K$439.84K–$297.78K$59.32K$1.21M+14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Aug 5, 2020
Exchange
Nasdaq
First trading day
Aug 4, 2020
First-day close
$11.40
Lock-up ends (est.)
Jan 31, 2021

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 86 employees engaged in finance, clinical, research and development, engineering, regulatory and administration functions.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 31, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 31, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 26, 2023Name changeName changed from Health Sciences Acquisitions Corp 2 to Orchestra BioMed Holdings, Inc.
Jan 24, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 8, 2022MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 5, 2020IPOInitial public offering priced (424B4 prospectus)
Aug 3, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?